跳转至内容
Merck
CN

937266

NanoFabTx for gene delivery

Maleimide lipid mix

登录 查看组织和合同定价。

选择尺寸


关于此项目

NACRES:
NA.21
UNSPSC Code:
12352142
Storage temp.:
−20°C
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

application(s)

advanced drug delivery

storage temp.

−20°C

Quality Level

正在寻找类似产品? 访问 产品对比指南

General description

Maleimide lipid mix for gene delivery and targeted delivery
The NanoFabTx gene delivery maleimide lipid mix is a ready-to-use nanoformulation lipid mixture for the synthesis of maleimide-functionalized lipid nanoparticles (LNPs).These lipid nanoparticles can be used for targeting and immunotherapy applications, and nucleic acid encapsulation.

This product is a curated lyophilized lipid mixture of rationally selected lipids in precise ratios that have been optimized to achieve a desired size range of lipid nanoparticles. Step-by-step protocols for the synthesis of maleimide-functionalized LNPs by microfluidics with the NanoFabTx microfluidic- nano device kit (Cat. No. 911593) or nanoprecipitiation are included.

Maleimide-functionalized LNPs are particularly advantageous for gene delivery because the maleimide functional group enables the conjugation of thiol-containing antibodies, proteins, aptamers, or other molecules to the lipid nanoparticle surface. This can be used for multi-targeting or multi-type cargo delivery to different cell types including immune cells, making it advantageous for many different therapuetic applications including mRNA vaccine delivery and oncology.

Application

With the NanoFabTx gene delivery maleimide lipid mix, researchers can simplify their drug development workflow. The ready to use mix enables the screening of different drug modalities such as oligonucleotides, nucleic acids (mRNA, DNA, siRNA), and vaccines without the need to develop new drug delivery formulations from scratch, ultimately speeding up the time it takes for innovative therapeutics to go from the bench to the clinic. The maleimide-functionalized surface of the LNP can be used to conjugate to many different thiol-containing biomolecules for active targeting. This ready-to-use lipid mix can also be used to screen different targeting moieties to determine what works best for your therapuetic and application. In addition, the lipid mix has been carefully crafted for enhanced gene delivery.

Features and Benefits

  • A ready-to-use nanoformulation lipid blend to synthesize Maleimide-functionalized lipid nanoparticles
  • Step-by-step protocols developed and tested by our formulation scientists
  • Flexible synthesis tool to create uniform and reproducible lipid nanoparticles
  • Optimized to make lipid nanoparticles around 100 nm with low polydispersity
  • Optimized lipid blend for thiol-containing protein or antibody conjugation
  • Optimized lipid blend for Maleimide-functionalized lipid nanoparticles for mRNA encapsulation
For more information, please refer to the protocol under the document section of this page.

Legal Information

Legal Information NanoFabTx is a trademark of Sigma-Aldrich Co. LLC
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

存储类别

11 - Combustible Solids

wgk

WGK 3

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Targeted delivery of lipid nanoparticle to lymphatic endothelial cells via anti-podoplanin antibody
Sakurai Y, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society, 349, 379-387 (2022)
Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment
Guo S, et al.
Exploration (Beijing, China), 1(1), 35-49 (2021)
István Tombácz et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 29(11), 3293-3304 (2021-06-07)
Nucleoside-modified messenger RNA (mRNA)-lipid nanoparticles (LNPs) are the basis for the first two EUA (Emergency Use Authorization) COVID-19 vaccines. The use of nucleoside-modified mRNA as a pharmacological agent opens immense opportunities for therapeutic, prophylactic and diagnostic molecular interventions. In particular
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
Tombacz I, et.al.
Molecular Therapy, 29(11), 3293-3304 (2021)
In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles
Fang-Yi S, et al.
Science advances, 8(8), eabm7950- eabm7950 (2022)

相关内容

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持